Previsão

O preço-alvo médio dos analistas é € 12,57 (+1.120,39%). A mediana é € 12,57 (+1.120,39%).

Comprar	4
Manter	1
Vender	0

Notícias Ir para o feed de notícias

Metagenomi presents progress in hemophilia program and plans IND submission

At the Wells Fargo Health Conference, Metagenomi presented preclinical advances in its lead in‑vivo CRISPR program MGX‑001 for hemophilia A, which aims to restore factor VIII to physiological levels and showed efficacy at substantially lower AAV doses. The company is targeting an IND submission for MGX‑001 in Q4 2024 and plans to start a global Phase I/II study in 2027. Management says Metagenomi has $120.7 million in cash, expected to fund operations through Q4 2027, and is advancing partnerships and additional programs. » Mais em de.investing.com
Metagenomi presents compact CRISPR tool MG119-28 with high editing efficiency in Nature

Metagenomi introduces MG119-28 in a study in Nature Structural & Molecular Biology — a compact Cas12f nuclease that the researchers report shows faster DNA cleavage and improved editing efficiency due to greater protein stability and a more stable guide RNA. The study, conducted with the University of Texas at Austin, builds on proof-of-concept data that demonstrated a 64% reduction of the Atxn2 protein in mice after AAV administration. The company is evaluating applications beyond hepatic indications, while the clinically active biotech, with a market value of $54 million, continues to burn cash and carries the typical development risks. » Mais em de.investing.com
Metagenomi renames itself and focuses gene‑therapy program for hemophilia A

Metagenomi has completed its rebranding and is prioritizing preclinical in‑vivo therapeutics, foremost the hemophilia A program MGX-001, which the company says showed curative factor VIII activity in non‑human primates without identifiable off‑target effects. After a pre‑IND meeting, Metagenomi plans to file IND/CTA applications in Q4 2026. The company expects financial runway into Q4 2027, reports more cash than debt but continues to burn cash; analysts see price targets of $7–12. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Metagenomi registou receitas de -€ 225,19 mil e um ganho líquido de -€ 24,08 mi

(EUR)	junho de 2026	YoY
Receitas	-225,19 mil	103,12%
Ganho bruto	-225,19 mil	98,10%
Ganho líquido	-24,08 mi	42,57%
EBITDA	-22,97 mi	46,13%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 37,85 mi
Número de ações	37,65 mi
Máximo/mínimo de 52 semanas	€ 3,42 - € 0,98
Dividendos	Não
Beta	0,68
PER (PE Ratio)	-0,47
PEG (PEG Ratio)	0,08
P/VC (PB Ratio)	0,39
P/V (PS Ratio)	3,22

Perfil da empresa

Metagenomi, Inc. ist ein Biotechnologieunternehmen im Bereich des Gen-Editings und entwickelt in den Vereinigten Staaten Therapeutika für Patienten unter Verwendung der aus der Metagenomik abgeleiteten Genome-Editing-Toolbox. Die Genom-Editierungs-Toolbox des Unternehmens umfasst programmierbare Nukleasen, Basen-Editoren und RNA- und DNA-vermittelte Integrationssysteme, wie z. B. Prime-Editierungssysteme und mit "clustered regularly interspaced short palindromic repeat-associated transposases". Es hat ein strategisches Kooperations- und Lizenzabkommen mit ModernaTX, Inc. mit Schwerpunkt auf neuen Genome-Editing-Systemen für therapeutische In-vivo-Anwendungen beim Menschen; ein Entwicklungs-, Options- und Lizenzabkommen mit Affini-T Therapeutics, Inc. zur Entwicklung und Vermarktung von gen-editierten T-Zell-Rezeptor-basierten therapeutischen Produkten im Bereich der Behandlung, Prävention oder Diagnose von menschlichem Krebs; und ein Kooperations- und Lizenzabkommen mit Ionis Pharmaceuticals, Inc. zur Erforschung, Entwicklung und Vermarktung von Prüfmedikamenten unter Verwendung von Genome-Editing-Technologien. Das Unternehmen wurde im Jahr 2016 gegründet und hat seinen Sitz in Emeryville, Kalifornien.

Nome	Metagenomi
CEO	Jian Irish
Sede	Emeryville, ca EUA
Site	metagenomi.co
Setor	Cuidados de saúde
Indústria	Biotecnologia
Entrada em bolsa	06/04/2006
Colaboradores	113